TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 33638221
Drug: Oral vancomycin
Normalized name: Vancomycin
DrugBank: Vancomycin (DB00512)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral vancomycin (OVT)
Study: 33424089
Drug: Group A:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group A: 1gr/8hours IV acetaminophen and 50mg/6hours IM pethidine
Study: 33424089
Drug: Group B:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group B: 1gr/8hours IV acetaminophen and 40mg/12hours IV parecoxib
Study: 33424089
Drug: Group C:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group C: 1gr/8hours IV acetaminophen monotherapy
Study: 33940389
Drug: Soticlestat (up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soticlestat (up to 300 mg BID)
Study: 32542873
Drug: Selective serotonin
Normalized name: Selective serotonin (5HT1) agonists
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selective serotonin reuptake inhibitors
Study: 34634436
Drug: Dose-escalated chemoradiation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose-escalated chemoradiation (5 × 3 gray boost + CRT)
Study: 34050531
Drug: Delayed delivery
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delayed delivery of an oral health intervention
Study: 33181560
Drug: Conventional oxygen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional oxygen therapy (Control)
Study: 33231489
Drug: AMG 301
Normalized name: AMG 108
DrugBank: AMG 108 (DB05545)
Approvals — FDA: no, EMA: no, PMDA: no
Description: AMG 301 420 mg every 2 weeks
Study: 35940353
Drug: Oxycodone group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxycodone group (10 mg extended-release oxycodone hydrochloride)
Study: 34256830
Drug: Telerehabilitation (smartphone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telerehabilitation (smartphone app with personalized program of resistance, balance, and daily activity training exercises)
Study: 35810307
Drug: Aspirin 75
Normalized name: aspirin 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin 75 mg (Group B)
Study: 35810307
Drug: Atorvastatin vs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin vs Control (Group D)
Study: 35810307
Drug: Aspirin vs
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin vs Control (Group D)
Study: 35810307
Drug: Both Atorvastatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both Atorvastatin and Aspirin (Group C)
Study: 33865929
Drug: PCIT-ED treatment
Normalized name: Ed-APAP
Approvals — FDA: no, EMA: no, PMDA: no
Description: PCIT-ED treatment (n = 64)
Study: 34098039
Drug: Pill counts
Normalized name: oteseconazole
DrugBank: Oteseconazole (DB13055)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pill counts adherence at 3 weeks
Study: 34098039
Drug: Pill counts
Normalized name: oteseconazole
DrugBank: Oteseconazole (DB13055)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pill counts adherence at 7 weeks
Study: 34098039
Drug: Agreement between
Normalized name: CYCLIZED P12 (PEPTIDE BOND BETWEEN THE CARBOXY AND AMINO-TERMINAL ENDS OF THE LINEAR PEPTIDE PSHISKYILRWRPK)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Agreement between self-report and pill counts at 3 weeks
Study: 34957959
Drug: Unimanual mirror
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Unimanual mirror therapy (UMT)
Study: 34957959
Drug: Bimanual mirror
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bimanual mirror therapy (BMT)
Study: 36174744
Drug: Placebo (0.9%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (0.9% saline solution)
Study: 33611380
Drug: Internet-based cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Internet-based cognitive behavioural therapy
Study: 33216613
Drug: TRK (Thor-Ra-Nee-San-Tha-Kat)
Normalized name: TRK-250
DrugBank: TRK-250 (DB18500)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TRK (Thor-Ra-Nee-San-Tha-Kat) - 500 mg capsules, 2 capsules once daily before bed for 14 days
Study: 33216613
Drug: Naproxen -
Normalized name: Naproxen
DrugBank: Naproxen (DB00788)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Naproxen - 250 mg tablets, 2 tablets twice a day after meals for 14 days
Study: 32756176
Drug: Yangxinshi (YXS)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yangxinshi (YXS) tablet
Study: 32424430
Drug: Continuation of
Normalized name: varenicline
DrugBank: Varenicline (DB01273)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Continuation of PD-1 pathway inhibitors
Study: 32348688
Drug: Strength training
Approvals — FDA: no, EMA: no, PMDA: no
Description: Strength training (ST) with vitamin C (500 mg/day) and E (180 mg/day) supplementation
Study: 33677172
Drug: Acupuncture with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture with low-level laser therapy (ALLLT)
Study: 32765053
Drug: Inhaled methoxyflurane
Normalized name: methoxyflurane Nasal Inhalant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled methoxyflurane (3 mL)
Study: 36043569
Drug: Control -
Normalized name: HISTAMINE 6 mg in 1 mL PERCUTANEOUS INJECTION [Positive Skin Test Control - Histamine]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control - no treatment
Study: 36055770
Drug: Moderate Spice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moderate Spice Diet (MSD) at 3.3 g.d-1.2100 kcal-1
Study: 36055770
Drug: High Spice
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High Spice Diet (HSD) at 6.6 g.d-1.2100 kcal-1
Study: 36055770
Drug: Low Spice
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low Spice Diet (LSD) at 0.5 g.d-1.2100 kcal-1
Study: 34872531
Drug: Nurse-led SRIT
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nurse-led SRIT treatment
Study: 34597298
Drug: 2-dose regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2-dose regimen of 5-μg NVX-CoV2373
Study: 34597298
Drug: 2-dose regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2-dose regimen of 25-μg NVX-CoV2373
Study: 39744861
Drug: Best medical
Normalized name: calcium polycarbophil
DrugBank: Calcium polycarbophil (DB14684)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Best medical treatment
Study: 32643454
Drug: Intradermal minoxidil
Normalized name: Minoxidil
DrugBank: Minoxidil (DB00350)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intradermal minoxidil 5% injections
Study: 32475067
Drug: Everolimus 2.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Everolimus 2.25 mg
Study: 32900662
Drug: Single 20-mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single 20-mg dexamethasone tablet (fasting)
Study: 32900662
Drug: Single 20-mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single 20-mg dexamethasone tablet (fed)
Study: 33944971
Drug: Euglycaemia (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Euglycaemia (5 mmol/l) with 20 mU [m2 BSA]‐1 min‐1 insulin (Eu20)
Study: 38749033
Drug: Chemotherapy plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy plus placebo
Study: 36332136
Drug: Probiotic supplement
Normalized name: Align Probiotic Supplement Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotic supplement (1 capsule/day for 8 weeks)
Study: 36653035
Drug: Probiotic supplement
Normalized name: Align Probiotic Supplement Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotic supplement
Study: 36202885
Drug: Placebo tablet
Normalized name: placebo Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablet consumed every hour for 4 h (PLA)
Study: 35486478
Drug: Oral hormonal
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral hormonal contraceptive pill (OC) during high estradiol (HE) phase
Study: 35486478
Drug: Oral hormonal
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral hormonal contraceptive pill (OC) during low estradiol (LE) phase
Study: 32931763
Drug: Spinal manipulation
Normalized name: Bos taurus spinal cord preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spinal manipulation therapy (3 sessions, 1 week apart, using Robert Maigne's technique)
Study: 37852649
Drug: atorvastatin
Normalized name: Atorvastatin
DrugBank: Atorvastatin (DB01076)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: atorvastatin
Study: 32441852
Drug: Fast enteral
Normalized name: Fast Freeze
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fast enteral advancement (30 mL/kg/d for 1000-1499 g; 40 mL/kg/d for 1500-1999 g)
Study: 32441852
Drug: Traditional enteral
Normalized name: lipase
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traditional enteral advancement (20 mL/kg/d)
Study: 33219727
Drug: Onlay preparation
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Onlay preparation with EverX Posterior (OE)
Study: 33219727
Drug: Onlay preparation
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Onlay preparation with G‐aenial Universal Flo (OG)
Study: 33219727
Drug: MOD inlay
Normalized name: MOD-423 hGH analogue
DrugBank: Somatrogon (DB14960)
Approvals — FDA: no, EMA: yes, PMDA: yes
Description: MOD inlay preparation with EverX Posterior (IE)
Study: 33219727
Drug: MOD inlay
Normalized name: MOD-423 hGH analogue
DrugBank: Somatrogon (DB14960)
Approvals — FDA: no, EMA: yes, PMDA: yes
Description: MOD inlay preparation with G‐aenial Universal Flo (IG)
Study: 33219727
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group without access cavity preparation (C)
Study: 33219727
Drug: Onlays with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Onlays with G‐aenial Universal Flo
Study: 32280282
Drug: EE 20
Normalized name: AcidFree 200mg Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: EE 20 mcg/DRSP 3 mg in an extended regimen (EE/DRSPes group)
Study: 33719786
Drug: Topical glaucoma
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical glaucoma medications (one-drug, two-drug, three-drug, four-drug regimens)
Study: 32232637
Drug: Rituximab (375
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rituximab (375 mg/m2, single intravenous infusion)
Study: 36890688
Drug: Antihypertensive treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antihypertensive treatment
Study: 35481707
Drug: TransCon CNP
Normalized name: TransCon CNP
DrugBank: ACP-015 (DB17824)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TransCon CNP (75-150 μg CNP/kg)
Study: 34293624
Drug: Guo Qing
Normalized name: Guo
DrugBank: Guanosine (DB02857)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guo Qing Yi Tang (GQYT) combined with Western medicine cluster therapy
Study: 32118347
Drug: Physician-managed titration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physician-managed titration of Gla-300
Study: 36779257
Drug: Lumateperone 42
Normalized name: lumateperone 42 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lumateperone 42 mg
Study: 36779257
Drug: Lumateperone 28
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lumateperone 28 mg
Study: 35551318
Drug: Monthly dual
Normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monthly dual injections
Study: 35551318
Drug: Monthly vaginal
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Monthly vaginal rings
Study: 33637926
Drug: Personalised Oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Personalised Oral Hygiene Advice (OHA)
Study: 34954864
Drug: Neoadjuvant FOLFOX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant FOLFOX chemotherapy
Study: 34843870
Drug: Single oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single oral dose of 25 μg of d3‐vitamin D3
Study: 34894316
Drug: Structured Postoperative
Normalized name: LIPID,STRUCTURED (FROM SUNFLOWER OIL)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Structured Postoperative Treatment (SPT)
Study: 36802321
Drug: Evolocumab 140
Normalized name: evolocumab 140 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Evolocumab 140 mg every 2 weeks (Q2W)
Study: 36608978
Drug: Cognitive Therapy
Normalized name: cognitive therapy software
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Therapy for Body Dysmorphic Disorder (CT‐BDD)
Study: 33875484
Drug: Insulin icodec
Normalized name: insulin icodec
DrugBank: Insulin icodec (DB16693)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin icodec titration A (prebreakfast self-measured blood glucose target 80-130 mg/dL; adjustment ±21 units/week; n = 51)
Study: 33875484
Drug: Insulin icodec
Normalized name: insulin icodec
DrugBank: Insulin icodec (DB16693)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin icodec titration B (80-130 mg/dL; ±28 units/week; n = 51)
Study: 33875484
Drug: Insulin icodec
Normalized name: insulin icodec
DrugBank: Insulin icodec (DB16693)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin icodec titration C (70-108 mg/dL; ±28 units/week; n = 52)
Study: 33875484
Drug: Insulin glargine
Normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Insulin glargine 100 units/mL (IGlar U100) (80-130 mg/dL; ±4 units/day; n = 51)
Study: 33875484
Drug: Insulin icodec
Normalized name: insulin icodec
DrugBank: Insulin icodec (DB16693)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin icodec titration B vs IGlar U100
Study: 34081614
Drug: Feminizing hormonal
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Feminizing hormonal treatment (GAHT) including natural estrogen (estradiol) and testosterone-blocking treatments such as cyproterone acetate, GnRH agonist, or spironolactone.
Study: 34081614
Drug: Cyproterone acetate
Normalized name: cyproterone acetate
DrugBank: Cyproterone acetate (DB04839)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyproterone acetate as anti-androgen treatment.
Study: 36097258
Drug: Oral ivermectin
Normalized name: Ivermectin
DrugBank: Ivermectin (DB00602)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral ivermectin (200 μg/kg body weight) twice, 1 week apart
Study: 36097258
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of BB plus ivermectin
Study: 33497715
Drug: JWH-018 (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: JWH-018 (75 μg/kg body weight)
Study: 36079749
Drug: 60 g
Normalized name: aspirin 60 Grains
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 g date fruit daily for 12 weeks
Study: 36079749
Drug: 60 g
Normalized name: aspirin 60 Grains
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 g raisins daily for 12 weeks
Study: 34537744
Drug: Intrathyroid steroid
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intrathyroid steroid injections
Study: 32718924
Drug: Usual care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual care (clinical consultations and routine monthly follow-up)
Study: 35959574
Drug: General treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: General treatment group
Study: 35475852
Drug: 0.015% ingenol
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.015% ingenol mebutate gel
Study: 32796456
Drug: Self-myofascial release
Normalized name: corticotropin
DrugBank: Corticotropin (DB01285)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Self-myofascial release therapy using the INYBI tool
Study: 32796456
Drug: Myofascial release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Myofascial release therapy (MRT) of the suboccipital muscles
Study: 34954424
Drug: Bethanechol (for
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bethanechol (for patients receiving 131I dose > 125mCi)
Study: 34871488
Drug: Monthly combined
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monthly combined injectable contraceptives (CIC)
Study: 34871488
Drug: Combined oral
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined oral contraceptive pills (COC)
Study: 32191598
Drug: Testosterone administration
Normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Testosterone administration (10 mg daily for 10 weeks)
Study: 35606235
Drug: S‐268019‐b recombinant
Approvals — FDA: no, EMA: no, PMDA: no
Description: S‐268019‐b recombinant protein vaccine (5 μg)
Study: 34326043
Drug: Co-trimoxazole 18
Normalized name: CO
DrugBank: Carbon monoxide (DB11588)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Co-trimoxazole 18 mg/kg two times per day (36 mg/kg/day) for 3 months
Study: 32616067
Drug: Daily hydroxychloroquine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily hydroxychloroquine
Study: 32425361
Drug: Lianhuaqingwen capsules
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lianhuaqingwen capsules (4 capsules, thrice daily for 14 days)
Study: 35708181
Drug: LYR‐210 (7500
Approvals — FDA: no, EMA: no, PMDA: no
Description: LYR‐210 (7500 µg)
Study: 35708181
Drug: LYR‐210 (2500
Approvals — FDA: no, EMA: no, PMDA: no
Description: LYR‐210 (2500 µg)
Study: 35511431
Drug: Tetravalent dengue
Normalized name: dengue virus live antigen, CYD serotype 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tetravalent dengue vaccine (TV005)
Study: 35511431
Drug: Trivalent admixture
Normalized name: brown mixture
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trivalent admixture vaccine
Study: 33138974
Drug: Renal replacement
Normalized name: Sus scrofa renal pelvis preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Renal replacement therapy
Study: 32015556
Drug: bNAb therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: bNAb therapy during ART interruption
Study: 38661512
Drug: Neoadjuvant therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant therapy
Study: 35477817
Drug: G-Premio Bond
Approvals — FDA: no, EMA: no, PMDA: no
Description: G-Premio Bond (GP)
Study: 33831316
Drug: HCV treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: HCV treatment prescribed
Study: 33831316
Drug: HCV treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: HCV treatment initiated
Study: 35421008
Drug: HBOC‐201 infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: HBOC‐201 infusion (up to 10 bags, equivalent to 3 units erythrocytes)
Study: 35421008
Drug: HBOC‐201 infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: HBOC‐201 infusion
Study: 33308110
Drug: Integrative mind-body-medicine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Integrative mind-body-medicine group program
Study: 32801202
Drug: 18 mg
Normalized name: niacin 18 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 18 mg ferrous bisglycinate
Study: 32207836
Drug: Ticagrelor and
Normalized name: Ticagrelor
DrugBank: Ticagrelor (DB08816)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ticagrelor and morphine without naloxone
Study: 33051342
Drug: PD-1/PD-L1 inhibitors
Approvals — FDA: no, EMA: no, PMDA: no
Description: PD-1/PD-L1 inhibitors (monotherapy)
Study: 32493473
Drug: Plasma‐Lyte 148
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plasma‐Lyte 148 Solution for Infusion (200mls)
Study: 35262624
Drug: HIPEC (41.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: HIPEC (41.5 °C, 75 mg/m2 of cisplatin, 90 minutes)
Study: 35262624
Drug: HIPEC (Interval
Approvals — FDA: no, EMA: no, PMDA: no
Description: HIPEC (Interval cytoreductive surgery after neoadjuvant chemotherapy)
Study: 35262624
Drug: Control (Interval
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (Interval cytoreductive surgery after neoadjuvant chemotherapy)
Study: 38896381
Drug: apremilast 30
Normalized name: apremilast 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: apremilast 30 mg twice daily
Study: 2010180594
Drug: Methylphenidate (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylphenidate (15 mg, twice a day for one month)
Study: 33975009
Drug: SARS-CoV-2 IgG
Normalized name: SARS-CoV-2 IgG
Approvals — FDA: no, EMA: no, PMDA: no
Description: SARS-CoV-2 IgG antibody levels
Study: 33479188
Drug: Everolimus (EVL)
Normalized name: Everolimus
DrugBank: Everolimus (DB01590)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Everolimus (EVL) with low-dose tacrolimus (Tac)
Study: 36071965
Drug: Probiotic chewable
Normalized name: Rezyst Probiotic Chewable Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotic chewable tablet (5 × 10^9 CFU/day, n = 47)
Study: 36198452
Drug: AVX001 gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: AVX001 gel 1%
Study: 36198452
Drug: AVX001 gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: AVX001 gel 3%
Study: 39630680
Drug: Vehicle gel
Normalized name: vehicle gel base no.61
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vehicle gel
Study: 36364734
Drug: Oat product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oat product providing 3 g of β‐Glucan
Study: 37697491
Drug: Self-administered questionnaire
Normalized name: corticotropin
DrugBank: Corticotropin (DB01285)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Self-administered questionnaire
Study: 32442355
Drug: Treatment as
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment as usual in the community
Study: 34967166
Drug: Tamsulosin monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamsulosin monotherapy
Study: 34844563
Drug: Nomogram model
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nomogram model for predicting prognosis of patients with CC
Study: 34996784
Drug: Anticoagulant treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anticoagulant treatment
Study: 34326035
Drug: Time to
Normalized name: Overtime Topical Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Time to First Systemic Treatment (TTFST)
Study: 33743237
Drug: Second intravenous
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Second intravenous immunoglobulin dose (SID) 2 g/kg over 5 days
Study: 32871021
Drug: Electromagnetic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Electromagnetic therapy
Study: 34991704
Drug: Azithromycin mass
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Azithromycin mass drug administration (MDA)
Study: 33881530
Drug: Sodium benzoate
Normalized name: Sodium Benzoate
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium benzoate (250 to 1500 mg/d)
Study: 34050261
Drug: Ionising radiation
Normalized name: allantoin
DrugBank: Allantoin (DB11100)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ionising radiation exposure (mean ABM dose 0.14 Gy)
Study: 32307658
Drug: Cognitive behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive behavioral therapy for insomnia (CBT-I) including sleep hygiene information, stimulus control, sleep restriction, and bedtime imagery audio recording.